Abstract: The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. The present disclosure also relates to methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.

Abstract: This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.

Abstract: The systems and methods can accurately and efficiently determine a myocardial risk from a lesion disposed along a coronary segment using hemodynamic characteristic(s) associated with one or more sections of the corresponding lesion site. The method may include segmenting one or more lesion sites disposed along at least one arterial segment of the one or more arterial segments of the coronary model into one or more sections. Each lesion site includes a lesion. The method may include determining one or more characteristics for at least one section using at least the one or more characteristics associated with the at least one arterial segment. The one or more characteristics for the at least one section including hemodynamic force characteristic(s) (e.g., wall shear stress (WSS)). The method may include determining one or more risk indices for each lesion site using at least the hemodynamic force characteristic(s) for the at least one section.

Abstract: This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.

Abstract: Delivery devices, systems, and methods may be configured to define a barrier region at a treatment site to deliver one or more therapeutic materials. A device for delivering one or more therapeutic materials to a treatment site may include a body; one or more members that are movable with respect to the body and that are configured to define a barrier region at the treatment site; and one or more delivery lumens configured to deliver one or more therapeutic materials to the barrier region.

Abstract: This disclosure relates to antibodies and antigen binding fragments that specifically bind Ebola virus particles. In certain embodiments, the antibodies and fragments are capable of treating or preventing an Ebola viral infection. In certain embodiments, the antibodies and antigen binding fragments are also contemplated for diagnostic methods and compositions related thereto.

Abstract: The systems and methods can automatically determine a patient-specific set of stimulation parameters using optimization for exploring and/or programming a neurostimulation device, e.g., deep brain stimulation (DBS). In one implementation, the method may include receiving patient data and set of stimulation parameters associated stimulation delivered to a patient by a neurostimulation device. The method may include determining one or more objective metrics using the patient data for each set of stimulation parameters. The one or more objective metrics may be a quantitative value that represents a rating or score of tremor severity and/or side effect severity. The method may further include generating a patient specific response model using the one or more objective metrics and the associated set of stimulation parameters. The method may also include applying an optimization algorithm to the generated response model to determine a candidate set of one or more stimulation parameters.

Abstract: Aspects of the subject disclosure may include, for example, a non-transitory, machine-readable medium, comprising executable instructions that, when executed by a processing system including a processor, facilitate performance of operations including receiving a call; selecting a next carrier to handoff the call; generating a call data record (CDR) for the handoff to the next carrier; encrypting the CDR using a call encryption key, thereby creating an encrypted CDR; encrypting the encrypted CDR using a committee encryption key, thereby creating a double encrypted CDR; recording the double encrypted CDR to a blockchain; and sending the call encryption key to the next carrier. Other embodiments are disclosed.

Abstract: This disclosure relates to methods of preserving mesenchymal stromal/stem cells (MSCs) for use in clinical applications. In certain embodiments, this disclosure relates to methods of preserving MSCs comprising mixing MSCs with interferon-gamma prior to cryopreserving, freezing, or cooling the MSCs to a temperature below zero degrees Celsius.

Abstract: The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

Abstract: This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Abstract: A method for diagnosing or giving a prognosis for anxious temperament or trait-like anxiety in a human or non-human primate subject comprising the steps of (a) obtaining DNA from a blood or saliva sample from the subject and (b) quantifying methylation in a set of differentially methylated regions (DMRs) selected from SEQ ID NOs: 1-32, 34-44, 46-53, and 55-74, GCTCA, CGCACCG, AGAGGCAG, and AGCTCG or DMR-associated genes selected from DIP2C, GRB10, INPP5A, C17ORF97, PDXK, CACNA2D4, TRAPPC9, CRTC1, MEGF6, HIVEP3, OPCML, PITPNM2, ZFPM1, RAP1GAP2, NFATC1, RNF126, FSTL3, GNAS, SH3BP2, NEURL1B, MAD1L1, HSPA12B, IGF2, PEG10, PEG3, SLC16A3, SYTL1, and ZIM2, wherein a significant change methylation indicates the present of anxious temperament or trait-like anxiety, wherein the change is relative to DNA from a second human or non-human primate who does not have anxious temperament or trait-like anxiety.

Abstract: This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.

Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides, nucleic acid molecules, and compositions disclosed herein to treat or prevent a viral infection.

Abstract: This disclosure relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

Abstract: In certain embodiments, this disclosure relates to KRAS agonists, pharmaceutical composition, and uses in managing cancer. In certain embodiments, the KRAS agonist is 4-(4-(2-bromoacetamido)butyl)benzoic acid, salt, prodrug, or derivative thereof. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of a compound of Formula I, salt, prodrug, or derivative thereof, to a subject in need thereof, wherein, substituents are reported herein.

Abstract: This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.

Abstract: Disclosed are methods for diagnosing declarative memory loss using mouse tracking to follow the visual gaze of a subject taking a visual paired comparison test. Also disclosed are methods for diagnosing dementia such as mild cognitive impairment and Alzheimer's disease.

Abstract: Described are recombinant nucleic acid molecules for increased expression of Cas9 in human liver. In some embodiments, the recombinant nucleic acid molecules are provided in compositions and methods for gene editing, specifically using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).

Abstract: Disclosed herein are novel variants of clotting factors VII, VIII, and IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.